Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

Merck
CN
All Photos(1)

Key Documents

View All Documentation

Y0000197

Ondansetron for LC system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Ondansetron hydrochloride dihydrate, 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydrochloride, GR 38032F

Sign Into View Organizational & Contract Pricing

Select a Size

10 MG
CN¥1,305.42

CN¥1,305.42

Estimated to ship onJune 04, 2025Details

Request a Bulk Order
All Photos(1)

Select a Size

Change View
10 MG
CN¥1,305.42

About This Item

Empirical Formula (Hill Notation):
C18H19N3O · HCl · 2H2O
CAS Number:
103639-04-9
Molecular Weight:
365.85
MDL number:
MFCD00374371
UNSPSC Code:
41116107
PubChem Substance ID:
329830879
NACRES:
NA.24

CN¥1,305.42

Estimated to ship onJune 04, 2025Details

Request a Bulk Order

grade

pharmaceutical primary standard

API family

ondansetron

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl[H].[H]O[H].[H]O[H].Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C

InChI

1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2

InChI key

VRSLTNZJOUZKLX-UHFFFAOYSA-N

Gene Information

human ... HTR3A(3359)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ondansetron for LC system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

5-HT3 serotonin receptor antagonist

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

PHR1141

Ondansetron Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

1478618

Ondansetron Related Compound C, United States Pharmacopeia (USP) Reference Standard

1478593

Ondansetron Related Compound A, United States Pharmacopeia (USP) Reference Standard

1478629

Ondansetron Related Compound D, United States Pharmacopeia (USP) Reference Standard

1478582

Ondansetron hydrochloride, United States Pharmacopeia (USP) Reference Standard

1478630

Ondansetron Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

PHR1181

2-Methylimidazole (Ondansetron Impurity F), Pharmaceutical Secondary Standard; Certified Reference Material

Y0000195

Ondansetron impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000196

Ondansetron for TLC system suitability, European Pharmacopoeia (EP) Reference Standard

Y0000218

Ondansetron hydrochloride dihydrate, European Pharmacopoeia (EP) Reference Standard

Y0001326

Ondansetron impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001320

Ondansetron impurity F, European Pharmacopoeia (EP) Reference Standard

Y0001345

Ondansetron impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001346

Ondansetron impurity G, European Pharmacopoeia (EP) Reference Standard

1478571

Ondansetron, United States Pharmacopeia (USP) Reference Standard

BP808

Ondansetron hydrochloride dihydrate, British Pharmacopoeia (BP) Reference Standard

BP806

Ondansetron impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR2224

Ondansetron Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2223

Ondansetron Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2221

Ondansetron Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

Signal Word

Danger

Hazard Statements

H301,H318,H410

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 2 - Eye Dam. 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number

    It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

    If you need assistance, please contact Customer Support.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Ali Mujtaba et al.
    Drug testing and analysis, 5(2), 122-125 (2013-02-16)
    A new, simple, rapid, accurate and precise high performance thin layer chromatography (HPTLC) method has been developed for the estimation of ondansetron hydrochloride in bulk and sublingual tablets. The mobile phase composition was chloroform : ethyl acetate : methanol :
    Björn Pasternak et al.
    The New England journal of medicine, 368(9), 814-823 (2013-03-01)
    Ondansetron is frequently used to treat nausea and vomiting during pregnancy, but the safety of this drug for the fetus has not been well studied. We investigated the risk of adverse fetal outcomes associated with ondansetron administered during pregnancy. From
    Roger M Browning et al.
    Regional anesthesia and pain medicine, 38(1), 39-43 (2012-10-30)
    Cesarean delivery is commonly performed under regional anesthesia, which is often associated with maternal shivering. This can cause distress and interfere with monitoring. The study objective was to evaluate the antishivering efficacy of ondansetron, which reduces the incidence and severity
    João Maria Corrêa Filho et al.
    Addictive behaviors, 38(4), 2044-2051 (2013-02-12)
    Ondansetron has emerged as a promising medication for the treatment of alcohol dependence, mainly among early-onset alcoholics. This research primarily aimed to evaluate the efficacy and safety of ondansetron at a 16mg/day dosage to treat alcohol-dependent outpatients. A double-blind, placebo-controlled
    Daniel Hervás et al.
    Pediatric emergency care, 28(11), 1166-1168 (2012-11-02)
    In this study, we determine the clinical impact of 1 dose of oral ondansetron for children with vomiting and evaluate the economic consequences of its use. The strategies compared were administering oral ondansetron in addition to oral rehydration therapy (group
    View All Related Papers

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service